{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:42:49Z","timestamp":1766158969943,"version":"3.41.2"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Men who have sex with men in China meet the definition of the population at \u201csubstantial risk\u201d of contracting human immunodeficiency virus (HIV) according to the World Health Organization; therefore, initiating pre-exposure prophylaxis (PrEP) is recommended for this population. Lack of convincing evidence on cost-effectiveness has resulted in the lack of large-scale PrEP implementation at a national level. The objective of this review is to assess the cost-effectiveness of pre-exposure prophylaxis implementation among men who have sex with men in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The following databases were used to search studies of pre-exposure prophylaxis in China in both English and Chinese: PubMed, Embase, the China National Knowledge Infrastructure (CNKI), and the Wanfang Database. Inclusion criteria included pre-exposure intervention, year for publication (2007\u20132021), setting (China), and cost-effectiveness estimation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven studies were identified. We found that pre-exposure prophylaxis is only cost-effective among men who have sex with men without prioritization with at least a 5.5% reduction in the market price in the models. Pre-exposure prophylaxis is potentially cost-effective when using the latest market price, combined with other preventive programs or delivered to the population with a high risk of HIV exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study identifies key considerations in cost-effectiveness evaluation: cost assumptions, implementation coverage, and targeted population. The scarce evidence available is not comparable to some extent. However, combined with the latest market and policy reform, the cost-effectiveness of PrEP could be achieved as estimated by the underlying model of the included studies. Consequently, it calls for more standard and transparent modeling studies that include the latest drug types and market prices.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.809268","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T05:42:50Z","timestamp":1655790170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in China: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Yuanqi","family":"Mi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengge","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/cid\/ciaa835","article-title":"The Enigma of the Human Immunodeficiency Virus (HIV) Epidemic in China","volume":"72","author":"Wu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B2","unstructured":"UNAIDS PCB Field vist to China 2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/S2352-3018(19)30293-0","article-title":"PrEP in China: choices are ahead","volume":"7","author":"Xu","year":"2020","journal-title":"Lancet HIV"},{"key":"B4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/sj.cr.7290359","article-title":"MSM and HIV\/AIDS in China","volume":"15","author":"Zhang","year":"2005","journal-title":"Cell Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e25242","DOI":"10.1002\/jia2.25242","article-title":"PrEP uptake preferences among men who have sex with men in China: results from a National Internet Survey","volume":"22","author":"Han","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1371\/journal.pctr.0020027","article-title":"Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial","volume":"2","author":"Peterson","year":"2007","journal-title":"PLoS Clin Trials"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"volume-title":"Tenofovir-based oral PrEP Prevents HIV infection among men who have sex with men in Western Chian: a multicenter, randomized, controled clinical trail","year":"2016","author":"Zeng","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/cid\/cit946","article-title":"A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia","volume":"58","author":"Schneider","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e25451","DOI":"10.1002\/jia2.25451","article-title":"Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries","volume":"23","author":"Pretorius","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e25653","DOI":"10.1002\/jia2.25653","article-title":"Assessing the performance of international pre-exposure prophylaxis (PrEP) eligibility guidelines in a cohort of Chinese MSM, Beijing, China 2009 to 2016","volume":"23","author":"Hall","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/cid\/ciz046","article-title":"US guideline criteria for human immunodeficiency virus preexposure prophylaxis: clinical considerations and caveats","volume":"69","author":"Calabrese","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/hiv.12724","article-title":"Summary of German-Austrian HIV PrEP guideline","volume":"20","author":"Spinner","year":"2019","journal-title":"HIV Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmii.2019.09.003","article-title":"Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention - 2018 update","volume":"53","author":"Yen-Hao Chu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","year":"2016","key":"B15"},{"key":"B16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.7999","article-title":"HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"Marrazzo","year":"2014","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.13419\/j.cnki.aids.2020.11.34","article-title":"Expert consensus on pre-exposure prophylaxis in China","volume":"26","author":"Xu","year":"2020","journal-title":"Chin J AIDS STD"},{"key":"B18","unstructured":"The mid-term summary meeting of MSM pre- and post-exposure prophylaxis pilot work was held in Yunnan 2019"},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.16505\/j.2095-0136.2020.0001","article-title":"Implementation plan for controlling HIV transmission (2019\u20132022)","volume":"10","year":"2020","journal-title":"Chin J Viral Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.3390\/ijerph16142620","article-title":"Willingness to Use and Adhere to HIV Pre-Exposure Prophylaxis (PrEP) among Men Who Have Sex with Men (MSM) in China","volume":"16","author":"Peng","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5582\/bst.2016.01035","article-title":"Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China","volume":"10","author":"Ding","year":"2016","journal-title":"Biosci Trends"},{"key":"B22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12889-020-08488-w","article-title":"Low willingness to pay for pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in China","volume":"20","author":"Cao","year":"2020","journal-title":"BMC Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijid.2018.08.006","article-title":"Adherence to pre-exposure prophylaxis among men who have sex with men: a prospective cohort study","volume":"75","author":"Qu","year":"2018","journal-title":"Int J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10461-017-1675-z","article-title":"A global estimate of the acceptability of pre-exposure prophylaxis for HIV among men who have sex with men: a systematic review and meta-analysis","volume":"22","author":"Peng","year":"2018","journal-title":"AIDS Behav"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6682932","DOI":"10.1155\/2021\/6682932","article-title":"Awareness of and preferences for preexposure prophylaxis (PrEP) among MSM at high risk of HIV infection in Southern China: findings from the T2T study","volume":"2021","author":"Chen","year":"2021","journal-title":"Biomed Res Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"A5","DOI":"10.1016\/j.jclinepi.2021.04.008","volume":"134","author":"PRISMA","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"A88","DOI":"10.1016\/j.jval.2015.03.517","article-title":"The WHO-CHOICE cost-effectiveness Threshold: a Country-level analysis of changes over time","volume":"18","author":"Griffiths","year":"2015","journal-title":"Value Health"},{"volume-title":"Economic evaluation of PrEP prevention strategy in MSM population","year":"2018","author":"Zhong","key":"B28"},{"key":"B29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.13419\/j.cnki.aids.2018.07.14","article-title":"Cost-effectiveness analysis of pre-exposure prophylaxis for men who have sex with men in China","volume":"24","author":"Fan","year":"2018","journal-title":"Chin J AIDS STD"},{"key":"B31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10461-018-2205-3","article-title":"Modelling the epidemiological impact and cost-effectiveness of PrEP for HIV transmission in MSM in China","volume":"23","author":"Zhang","year":"2019","journal-title":"AIDS Behav"},{"key":"B32","doi-asserted-by":"publisher","first-page":"11641","DOI":"10.1038\/s41598-018-30101-9","article-title":"Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"volume-title":"The simulation study on epidemiologic and economic impact of pre-exposure prophylaxis for men who have sex with men in China","year":"2018","author":"Wei","key":"B33"},{"key":"B34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12879-018-3516-8","article-title":"A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China","volume":"18","author":"Li","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/s12879-019-4275-x","article-title":"Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study","volume":"19","author":"Hu","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/QAD.0b013e32830e00f5","article-title":"Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness","volume":"22","author":"Desai","year":"2008","journal-title":"AIDS"},{"key":"B37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1086\/597095","article-title":"HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness","volume":"48","author":"Paltiel","year":"2009","journal-title":"Clin Infect Dis"},{"volume-title":"Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. WHO Guidelines Approved by the Guidelines Review Committee","year":"","key":"B38"},{"key":"B39","unstructured":"GenevaGuidance on Oral pre-Exposure Prophylaxis (PrEP) for Serodis- Cordant Couples, Men and Transgender Women Who Have Sex With Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects2012"},{"key":"B40","unstructured":"National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog issued by The Ministry of Human Resources and Social Security(2017 Edition) 2017"},{"key":"B41","unstructured":"Notice on Limiting the Price of the Drugs of Other Enterprises with the Same Generic Name of the Nationally-selected Drugs"},{"key":"B42","unstructured":"Notice on Publicizing the Price Adjustment of the Fourth Batch of Unselected Drugs in National Centralized Procurement 2021"},{"key":"B43","unstructured":"Letter on Reply to Proposal No. 3707 (Medical Sports No. 453) of the Fifth Session of the Twelfth National Committee of the Chinese People's Political Consultative Conference"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-020-01419-4","article-title":"Lamivudine\/Tenofovir Disoproxil fumarate is an appropriate PrEP REGIMEN","volume":"80","author":"Mujugira","year":"2020","journal-title":"Drugs"},{"key":"B45","unstructured":"Notice on the announcement of the decryption results of the eighth batch of direct listing (batch 1 supplementary, batch 2) and low-cost drug supplementary listing 2019"},{"key":"B46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.7326\/M21-1548","article-title":"Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis","volume":"175","author":"Neilan","year":"2022","journal-title":"Ann Intern Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/01.NAJ.0000654288.99137.49","article-title":"Descovy approved for HIV prexposure prophylaxis","volume":"120","author":"Aschenbrenner","year":"2020","journal-title":"AJN"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1001401","DOI":"10.1371\/journal.pmed.1001401","article-title":"The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies","volume":"10","author":"Gomez","year":"2013","journal-title":"PLoS Med"},{"key":"B49","unstructured":"Gilead Says Generic Truvada Will Be Available in 20202019"},{"key":"B50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.7326\/M19-3478","article-title":"Comparative pricing of branded tenofovir alafenamide-emtricitabine relative to generic tenofovir disoproxil fumarate-emtricitabine for HIV preexposure prophylaxis: a cost-effectiveness analysis","volume":"172","author":"Walensky","year":"2020","journal-title":"Ann Intern Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jval.2021.02.005","article-title":"Cost-effectiveness analysis of a national pre-exposure prophylaxis (PrEP) program in Ireland","volume":"24","author":"O'Murchu","year":"2021","journal-title":"Value Health"},{"key":"B52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12889-020-8334-4","article-title":"Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel","volume":"20","author":"Ginsberg","year":"2020","journal-title":"BMC Public Health"},{"key":"B53","unstructured":""},{"key":"B54","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jval.2020.01.016","article-title":"Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling","volume":"23","author":"Marshall","year":"2020","journal-title":"Value Health"},{"key":"B55","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1071\/SH18065","article-title":"Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand","volume":"15","author":"Phanuphak","year":"2018","journal-title":"Sex Health"},{"key":"B56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1473-3099(22)00081-0","article-title":"Updates in pre-exposure prophylaxis for HIV","volume":"22","author":"Mushtaq","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JNC.0000000000000218","article-title":"Facilitators and barriers of HIV self-testing among Chinese men who have sex with men: a qualitative study","volume":"32","author":"Zhang","year":"2021","journal-title":"J Assoc Nurses AIDS Care"},{"key":"B58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1478-7547-5-13","article-title":"A cost function for HIV prevention services: is there a 'u' - shape?","volume":"5","author":"Guinness","year":"2007","journal-title":"Cost Eff Resour Alloc"},{"key":"B59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-156-8-201204170-00001","article-title":"The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men","volume":"156","author":"Juusola","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.809268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T05:43:03Z","timestamp":1655790183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.809268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":59,"alternative-id":["10.3389\/fpubh.2022.809268"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.809268","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"article-number":"809268"}}